Yongzhi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yongzhi Wang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Anna Wang
Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
1 shared publication- Brandi Watts
Department of Biological Sciences, Southeastern Oklahoma State University, Durant, OK, 74701, USA.
1 shared publication - Chong Li
CAS, Key Lab of Mental Health, Institute of Psychology, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 101408, China
1 shared publication - Er-Hu Jin
Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
1 shared publication Jingjie Zhao
CAS, Key Lab of Mental Health, Institute of Psychology, Beijing 100101, China; Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
1 shared publicationLi Li
Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
1 shared publication
Latest Publications
- Open Access
- 1 September 2019
- Published by Elsevier in Journal of Affective Disorders
- Vol. 256, 117-124
Depression comorbid with hyperalgesia: Different roles of neuroinflammation induced by chronic stress and hypercortisolism
- 1 September 2019
- Published by Elsevier in Journal of Affective Disorders
- Vol. 256, 117-124
Open AccessDepression comorbid with hyperalgesia: Different roles of neuroinflammation induced by chronic stress and hypercortisolism
- Open Access
- 2 May 2015
- Published by Springer Nature in BMC Psychiatry
- Vol. 15 (1) , 1-7
A MRS study of metabolic alterations in the frontal white matter of major depressive disorder patients with the treatment of SSRIs
Proton magnetic resonance spectroscopy provides a non-invasive technology to study brain metabolite levels in vivo, which can be used to measure biochemical compounds or metabolite concentrations in circumscribed brain regions. Previous research has highlighted the role of glial cells in brain white matter. It has been assumed that antidepressant treatment with SSRIs not only affects neurons, but also activates glial cells. This study focused on the observation of any potential changes in the metabolite levels of the ventral prefrontal white matter in major depressive disorder (MDD) patients who have received antidepressant treatment. 17 female patients diagnosed as MDD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria with the scores of 18 and above on the 24-item Hamilton Depression Rating Scale (HDRS) were recruited. MRS studies were performed on a 3.0 T MR system, single voxel PRESS spectroscopy with chemical-shift selective saturation water suppression. The volume of interest was localized at the bilateral ventral prefrontal white matter regions (voxel size: 2 × 2 × 2 mm3). The spectral data analysis was performed by using the instrument manufacturer supplied software. The bilateral ventral prefrontal white matter of MDD patients showed significantly lower Cho/Cr (p < 0.05) before receiving treatment. The HDRS, as the indicator of treatment response, showed a significant decrease in patients who had gone through 12 weeks treatment (p < 0.01). The bilateral Cho/Cr values of post-treatment patients were increased significantly compared to that of pre-treatment (p < 0.05). The alteration of ventral prefrontal white matter metabolite levels are likely involved in MDD pathophysiology and imply a crucial role of white matter in MDD.
- 2 May 2015
- Published by Springer Nature in BMC Psychiatry
- Vol. 15 (1) , 1-7
Open AccessA MRS study of metabolic alterations in the frontal white matter of major depressive disorder patients with the treatment of SSRIs
Proton magnetic resonance spectroscopy provides a non-invasive technology to study brain metabolite levels in vivo, which can be used to measure biochemical compounds or metabolite concentrations in circumscribed brain regions. Previous research has highlighted the role of glial cells in brain white matter. It has been assumed that antidepressant treatment with SSRIs not only affects neurons, but also activates glial cells. This study focused on the observation of any potential changes in the metabolite levels of the ventral prefrontal white matter in major depressive disorder (MDD) patients who have received antidepressant treatment. 17 female patients diagnosed as MDD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria with the scores of 18 and above on the 24-item Hamilton Depression Rating Scale (HDRS) were recruited. MRS studies were performed on a 3.0 T MR system, single voxel PRESS spectroscopy with chemical-shift selective saturation water suppression. The volume of interest was localized at the bilateral ventral prefrontal white matter regions (voxel size: 2 × 2 × 2 mm3). The spectral data analysis was performed by using the instrument manufacturer supplied software. The bilateral ventral prefrontal white matter of MDD patients showed significantly lower Cho/Cr (p < 0.05) before receiving treatment. The HDRS, as the indicator of treatment response, showed a significant decrease in patients who had gone through 12 weeks treatment (p < 0.01). The bilateral Cho/Cr values of post-treatment patients were increased significantly compared to that of pre-treatment (p < 0.05). The alteration of ventral prefrontal white matter metabolite levels are likely involved in MDD pathophysiology and imply a crucial role of white matter in MDD.